Identification of a Circulating MicroRNA Signature for Colorectal Cancer Detection
暂无分享,去创建一个
Mei Zhao | Mei Zhao | Mei-hua Yang | Jia Wang | Sheng-kai Huang | Mei Yang | Jia-ling Zhong | Yu-yu Gu | Hua Peng | Yi-qun Che | Chang-zhi Huang | Sheng-kai Huang | Chang-zhi Huang | Jia-ling Zhong | Jia Wang | Yi-Qun Che | Yu-yu Gu | Hua Peng | Shengkai Huang
[1] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[2] H. Matsubara,et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma , 2013, British Journal of Cancer.
[3] Wei Zhang,et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. , 2012, Cancer letters.
[4] C. Ko,et al. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. , 2005, Journal of the National Cancer Institute.
[5] N. Sata,et al. Plasma biomarker discovery and validation for colorectal cancer by quantitative shotgun mass spectrometry and protein microarray , 2011, Cancer science.
[6] R. Weinberg,et al. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. , 2010, Cancer research.
[7] X. Chen,et al. Identification of ten serum microRNAs from a genome‐wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis , 2011, International journal of cancer.
[8] Xi Chen,et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. , 2011, European journal of cancer.
[9] Sofie Nilsson,et al. Downregulation of miR-92a Is Associated with Aggressive Breast Cancer Features and Increased Tumour Macrophage Infiltration , 2012, PloS one.
[10] Keith W. Jones,et al. Impact of Cellular miRNAs on Circulating miRNA Biomarker Signatures , 2011, PloS one.
[11] P Glasziou,et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. , 2007, The Cochrane database of systematic reviews.
[12] Francesco Tomasello,et al. miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors , 2009, Journal of Neuro-Oncology.
[13] M Westwood,et al. Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic review , 2007, Journal of medical screening.
[14] F. Slack,et al. Small non-coding RNAs in animal development , 2008, Nature Reviews Molecular Cell Biology.
[15] Sheng Wang,et al. Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer , 2013, Clinical and Translational Oncology.
[16] Robert A. Weinberg,et al. A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .
[17] D. Berger,et al. MicroRNA and Colorectal Cancer , 2009, World Journal of Surgery.
[18] Qinghua Xu,et al. Plasma miR-601 and miR-760 Are Novel Biomarkers for the Early Detection of Colorectal Cancer , 2012, PloS one.
[19] X. Chen,et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.
[20] E. Kroh,et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.
[21] Wanjun Yu,et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. , 2011, Biochemical and biophysical research communications.
[22] L. Hood,et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.
[23] Pedro Larrañaga,et al. Identification of a biomarker panel for colorectal cancer diagnosis , 2012, BMC Cancer.
[24] P. Glasziou,et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. , 1998, BMJ.
[25] Y. Gong,et al. Combination of plasma microRNAs with serum CA19‐9 for early detection of pancreatic cancer , 2012, International journal of cancer.
[26] Y. Nagakawa,et al. Deregulation of miR‐92a expression is implicated in hepatocellular carcinoma development , 2010, Pathology international.
[27] B. Xiao,et al. Down-regulation of miR-31 expression in gastric cancer tissues and its clinical significance , 2010, Medical oncology.
[28] Junxia Zhang,et al. hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells , 2008, Brain Research.
[29] M. L. Hastings,et al. Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells , 2010, PloS one.
[30] N. Miller,et al. MicroRNAs in colorectal cancer: function, dysregulation and potential as novel biomarkers. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[31] G. Kristiansen,et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.
[32] X. Gu,et al. microRNA expression profiles in human colorectal cancers with brain metastases. , 2012, Oncology letters.
[33] Keith W. Jones,et al. The curious case of miRNAs in circulation: potential diagnostic biomarkers? , 2013, Wiley interdisciplinary reviews. RNA.
[34] Feng-jun Wang,et al. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. , 2010, Gynecologic oncology.
[35] Zhaoli Chen,et al. microRNA-92a Promotes Lymph Node Metastasis of Human Esophageal Squamous Cell Carcinoma via E-Cadherin* , 2010, The Journal of Biological Chemistry.
[36] M. Duffy,et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. , 2007, European journal of cancer.